Related Experiment Video

Updated: Aug 17, 2026

Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma
08:07

Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma

Published on: April 12, 2019

6.7K

HER-2 involvement in osteosarcoma

Jonathan Gill1, David Geller, Richard Gorlick

  • 1Department of Pediatrics, Montefiore Medical Center, The Children's Hospital at Montefiore, 3415 Bainbridge Avenue, Rosenthal 3rd Floor, Bronx, NY, USA.

Advances in Experimental Medicine and Biology
|June 14, 2014
PubMed

Insights

Research on the epidermal growth factor receptor pathway in osteosarcoma, specifically HER-2, yielded conflicting results on its expression and prognostic value. This review discusses findings and therapeutic targeting strategies for osteosarcoma treatment.

Area of Science:

  • Oncology
  • Translational Research
  • Molecular Biology

Background:

  • The epidermal growth factor receptor (EGFR) pathway is crucial in various cancers.
  • HER-2 expression has been observed in a subset of osteosarcoma cases.
  • Previous research on HER-2 in osteosarcoma has produced inconsistent findings.

Purpose of the Study:

  • To review and discuss the existing literature on HER-2 expression in osteosarcoma.
  • To analyze the prognostic value of HER-2 in osteosarcoma.
  • To explore therapeutic strategies targeting the HER-2 pathway in osteosarcoma.

Main Methods:

  • Literature review and critical analysis of published studies on HER-2 in osteosarcoma.
  • Discussion of conflicting reports regarding HER-2 expression levels and prognostic significance.
  • Examination of therapeutic approaches targeting HER-2, including trastuzumab treatment.

Main Results:

  • Conflicting reports exist regarding the level and prognostic value of HER-2 expression in osteosarcoma.
  • The HER-2 pathway has been investigated as a potential therapeutic target.
  • At least one clinical study using trastuzumab for osteosarcoma treatment has been completed.

Conclusions:

  • Further research is needed to clarify the role of HER-2 in osteosarcoma.
  • Targeting the HER-2 pathway represents a potential therapeutic avenue for osteosarcoma.
  • Lessons learned from previous investigations can guide future translational research in osteosarcoma.

More Related Videos

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

6.5K
A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate07:31

A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate

Published on: May 3, 2021

3.3K

Related Concept Videos

Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Metastasis02:30

Metastasis

Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...